



# SAFETY DATA SHEET

Revision date 02-Feb-2022

Version 2.02

Page 1 / 11

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

Product Name	Nirmatrelvir Film-Coated Tablets
Product Code(s)	PF00278
Synonyms	PF-07321332 (IR) Film-Coated Tablets; Paxlovid
Trade Name:	Not applicable
Chemical Family:	Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use	Pharmaceutical product
-----------------	------------------------

### 1.3. Details of the supplier of the safety data sheet

Pfizer Inc  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

### 1.4. Emergency telephone number

Emergency Telephone	Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887
E-mail address	pfizer-MSDS@pfizer.com

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous

### 2.2. Label elements

Signal word	Not classified
Hazard statements	Not classified in accordance with international standards for workplace safety.
Supplemental Hazard	Compound, not fully tested, hazards unknown.

### 2.3. Other hazards

Other hazards	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
---------------	---

Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
-------	---

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 2 / 11  
Version 2.02

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Microcrystalline cellulose 9004-34-6	*		232-674-9	No data available	Not Listed	No data available	No data available
Lactose Monohydrate 89466-76-2	*		Not Listed	No data available	Not Listed	No data available	No data available
Nirmatrelvir 2628280-40-8	15 - 20		Not Listed	No data available	Not Listed	No data available	No data available
Opadry Pink MIXTURE	*		Not Listed	No data available	Not Listed	No data available	No data available
Croscarmellose sodium 74811-65-7	*		Not Listed	No data available	Not Listed	No data available	No data available
Sodium stearyl fumarate 4070-80-8	*		223-781-1	No data available	Not Listed	No data available	No data available
+ Silicon dioxide, NF 7631-86-9	< 1		231-545-4	No data available	Not Listed	No data available	No data available

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Microcrystalline cellulose 9004-34-6	5000	2000	5.8	No data available	No data available
+ Silicon dioxide, NF 7631-86-9	7900	5000	58.8	No data available	No data available

### Additional information

+ Substance with a Union workplace exposure limit  
- Not Assigned

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 3 / 11  
Version 2.02

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
-------------------------------------	--

### 4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.
--------------------	-------

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

Suitable Extinguishing Media	Dry chemical, CO <sub>2</sub> , alcohol-resistant foam or water spray.
------------------------------	--

### 5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	Fine particles (such as dust and mists) may fuel fires/explosions.
Hazardous combustion products	Formation of toxic gases is possible during heating or fire. May include oxides of carbon, nitrogen and products of fluorine.

### 5.3. Advice for firefighters

Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.
--	--

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders	Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
---------------------------	--

### 6.3. Methods and material for containment and cleaning up

Methods for containment	Prevent further leakage or spillage if safe to do so.
-------------------------	---

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 4 / 11  
Version 2.02

**Methods for cleaning up** Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean spill area thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

## 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## **Section 7: HANDLING AND STORAGE**

### 7.1. Precautions for safe handling

#### **Advice on safe handling**

Ground and bond all bulk transfer equipment. Avoid open handling. Minimize dust generation. Use local exhaust ventilation or perform work under fume hood/fume cupboard. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

### 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical drug product.

## **Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

### 8.1. Control parameters

#### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

#### **Microcrystalline cellulose**

ACGIH TLV	10 mg/m <sup>3</sup>
Denmark	1 mg/m <sup>3</sup>
Estonia	10 mg/m <sup>3</sup>
	2 mg/m <sup>3</sup>
France	10 mg/m <sup>3</sup>
	1 mg/m <sup>3</sup>
Hungary	3 mg/m <sup>3</sup>
Ireland	10 mg/m <sup>3</sup>
	STEL: 30 mg/m <sup>3</sup>
Latvia	2 mg/m <sup>3</sup>
	6 mg/m <sup>3</sup>
Poland	3 mg/m <sup>3</sup>
Romania	10 mg/m <sup>3</sup>
Russia	TWA: 6 mg/m <sup>3</sup>
	MAC: 10 mg/m <sup>3</sup>
Spain	10 mg/m <sup>3</sup>
Switzerland	3 mg/m <sup>3</sup>
	2 mg/m <sup>3</sup>
OSHA PEL	15 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
	(vacated) TWA: 15 mg/m <sup>3</sup> total dust
	(vacated) TWA: 5 mg/m <sup>3</sup> respirable fraction

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 5 / 11  
Version 2.02

United Kingdom	(vacated) TWA: 5 mg/m <sup>3</sup> (vacated) STEL: 10 mg/m <sup>3</sup> TWA: 10 mg/m <sup>3</sup> TWA: 4 mg/m <sup>3</sup> STEL: 20 mg/m <sup>3</sup> STEL: 12 mg/m <sup>3</sup>
<b>+ Silicon dioxide, NF</b>	
Austria	4 mg/m <sup>3</sup>
Bulgaria	0.1 mg/m <sup>3</sup>
Czech Republic	0.1 mg/m <sup>3</sup> 4.0 mg/m <sup>3</sup>
Estonia	2 mg/m <sup>3</sup>
European Union	TWA: 0.1 mg/m <sup>3</sup>
Finland	5 mg/m <sup>3</sup> 0.05 mg/m <sup>3</sup> 0.1 mg/m <sup>3</sup> 0.5 mg/m <sup>3</sup> Ceiling / Peak: 4 mg/m <sup>3</sup>
Germany	4 mg/m <sup>3</sup>
Germany	6 mg/m <sup>3</sup>
Ireland	2.4 mg/m <sup>3</sup> STEL: 18 mg/m <sup>3</sup> STEL: 7.2 mg/m <sup>3</sup>
Italy	0.1 mg/m <sup>3</sup>
Latvia	1 mg/m <sup>3</sup> 0.1 mg/m <sup>3</sup>
Netherlands	0.75 mg/m <sup>3</sup>
Russia	TWA: 1 mg/m <sup>3</sup> TWA: 2 mg/m <sup>3</sup> TWA: 4 mg/m <sup>3</sup> MAC: 3 mg/m <sup>3</sup> MAC: 6 mg/m <sup>3</sup>
Switzerland	4 mg/m <sup>3</sup>
OSHA PEL	50 µg/m <sup>3</sup> (vacated) TWA: 6 mg/m <sup>3</sup> <1% Crystalline silica 20 mppcf
United Kingdom	TWA: 6 mg/m <sup>3</sup> TWA: 2.4 mg/m <sup>3</sup> TWA: 0.1 mg/m <sup>3</sup> STEL: 18 mg/m <sup>3</sup> STEL: 7.2 mg/m <sup>3</sup>

## Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

## Nirmatrelvir

Pfizer Occupational Exposure Band (OEB):

OEB 3 - Contact Hazards Unknown (control exposure to the range of 10µg/m<sup>3</sup> to < 100µg/m<sup>3</sup>)

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels to below the OEB range.

### Environmental exposure controls

No information available.

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 6 / 11  
Version 2.02

<b>Personal protective equipment</b>	Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
<b>Eye/face protection</b>	Wear safety goggles as minimum protection. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
<b>Hand protection</b>	Wear 2 layers of impervious disposable gloves (e.g. Nitrile, etc.) to prevent skin contact. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
<b>Skin and body protection</b>	Wear impervious protective clothing to prevent skin contact – consider use of disposable clothing where appropriate. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
<b>Respiratory protection</b>	Under normal conditions of use, if the applicable Occupational Exposure Band (OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).
<b>General hygiene considerations</b>	Handle in accordance with good industrial hygiene and safety practice.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

<b>Physical state</b>	Tablet
<b>Color</b>	White to pink
<b>Odor</b>	No information available.
<b>Odor threshold</b>	No information available
<b>Molecular formula</b>	Mixture
<b>Molecular weight</b>	Mixture
<b>Property</b>	<b>Values</b>
<b>pH</b>	No data available
<b>Melting point / freezing point</b>	No data available
<b>Boiling point / boiling range</b>	
<b>Flash point</b>	No information available
<b>Evaporation rate</b>	No data available
<b>Flammability (solid, gas)</b>	No data available
<b>Flammability Limit in Air</b>	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
<b>Vapor pressure</b>	No data available
<b>Vapor density</b>	No data available
<b>Relative density</b>	No data available
<b>Water solubility</b>	No data available
<b>Solubility(ies)</b>	No data available
<b>Partition coefficient</b>	No data available
<b>Autoignition temperature</b>	No data available
<b>Decomposition temperature</b>	No data available
<b>Kinematic viscosity</b>	No data available
<b>Dynamic viscosity</b>	No data available
<b>Particle characteristics</b>	

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 7 / 11  
Version 2.02

**Particle Size**  
**Particle Size Distribution**  
**Explosive properties**

No information available  
No information available  
No information available

## **Partition Coefficient: (Method, pH, Endpoint, Value)**

Nirmatrelvir  
Predicted 7.4 Log D 1.591

## **9.2. Other information**

No information available

### **9.2.1. Information with regard to physical hazard classes**

No information available

### **9.2.2. Other safety characteristics**

No information available

## **Section 10: STABILITY AND REACTIVITY**

### **10.1. Reactivity**

**Reactivity** No data available.

### **10.2. Chemical stability**

**Stability** Stable under normal conditions.

### **Explosion data**

**Sensitivity to Mechanical Impact** No data available.

**Sensitivity to Static Discharge** No data available.

### **10.3. Possibility of hazardous reactions**

**Possibility of hazardous reactions** No information available.

### **10.4. Conditions to avoid**

**Conditions to avoid** Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from electrostatic discharge.

### **10.5. Incompatible materials**

**Incompatible materials** As a precautionary measure, keep away from strong oxidizers.

### **10.6. Hazardous decomposition products**

**Hazardous decomposition products** No data available.

## **Section 11: TOXICOLOGICAL INFORMATION**

### **11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008**

#### **General Information:**

Toxicological properties have not been thoroughly investigated.

#### **Known Clinical Effects:**

Based on clinical trials in humans, possible adverse effects following exposure to this compound may include: Inflammation of the nasal passages (nasopharyngitis), dizziness, headache, diarrhea, nausea, and vomiting.

#### **Acute Toxicity: (Species, Route, End Point, Dose)**

##### **Microcrystalline cellulose**

Rat Oral LD50 > 5000 mg/kg

Rabbit Dermal LD50 > 2000 mg/kg

##### **Nirmatrelvir**

Rat Oral NOAEL 1000 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Microcrystalline cellulose	> 5 g/kg ( Rat )	> 2000 mg/kg ( Rabbit )	> 5800 mg/m <sup>3</sup> ( Rat ) 4 h
+ Silicon dioxide, NF	= 7900 mg/kg ( Rat )	> 5000 mg/kg ( Rabbit )	> 58.8 mg/L ( Rat ) 4 h

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 8 / 11  
Version 2.02

--	--	--	--

**Safety Pharmacology:** **PF-07321332:** Neurofunction: not significant. Pulmonary: increased respiratory rate, (1000 mg/kg). *In vivo* Cardiovascular: decreased heart rate, increase blood pressure, (150 (75 BID) mg/kg).

## **Irritation / Sensitization: (Study Type, Species, Severity)**

### **Microcrystalline cellulose**

Skin irritation Rabbit Non-irritating

Eye irritation Rabbit Non-irritating

## **Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

### **Nirmatrelvir**

14 Day(s) Rat Oral 1000 mg/kg/day NOAEL None identified

14 Day(s) Monkey Oral 600 (300 BID) mg/kg/day NOAEL None identified

1 Month(s) Rat Oral 1000 mg/kg/day NOAEL None identified

1 Month(s) Monkey Oral 600 (300 BID) mg/kg/day NOAEL None identified

## **Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **Nirmatrelvir**

Embryo / Fetal Development Rat Oral 1000 mg/kg/day NOAEL Maternal toxicity, Developmental toxicity

Embryo / Fetal Development Rabbit Oral 1000 mg/kg/day NOAEL Maternal Toxicity

Embryo / Fetal Development Rabbit Oral 300 mg/kg/day NOAEL Developmental toxicity

Reproductive & Fertility Rat Oral M / F 1000 mg/kg/day NOAEL Paternal toxicity, Fertility

## **Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

### **Nirmatrelvir**

Bacterial Mutagenicity (Ames) *Salmonella* , *E. coli* Negative

*In Vitro* Cytogenetics TK6 cells Negative

*In Vivo* Micronucleus Rat Bone marrow Negative

### **Carcinogenicity** **+ Silicon dioxide, NF**

Not listed as a carcinogen by IARC, NTP or US OSHA.

IARC

Group 3 (Not Classifiable)

## **11.2. Information on other hazards**

### **11.2.1. Endocrine disrupting properties**

**Endocrine disrupting properties** No information available.

### **11.2.2. Other information**

**Other adverse effects** No information available.

## **Section 12: ECOLOGICAL INFORMATION**

**Environmental Overview:** Releases to the environment should be avoided. Environmental properties have not been investigated.

### **12.1. Toxicity**

**No information available**

### **12.2. Persistence and degradability**

**Persistence and degradability** No information available.



# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 9 / 11  
Version 2.02

## 12.3. Bioaccumulative potential

### Bioaccumulation

#### Partition Coefficient: (Method, pH, Endpoint, Value)

##### Nirmatrelvir

Predicted 7.4 Log D 1.591

## 12.4. Mobility in soil

**Mobility in soil** No information available.

## 12.5. Results of PBT and vPvB assessment

### PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
+ Silicon dioxide, NF	The substance is not PBT / vPvB PBT assessment does not apply

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

## 12.7. Other adverse effects

No information available.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Microcrystalline cellulose

CERCLA/SARA Section 313 de minimus %

Not Listed

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 10 / 11  
Version 2.02

<b>California Proposition 65</b>	carcinogen 12/18/2009
<b>TSCA</b>	Present
<b>EINECS</b>	232-674-9
<b>AICS</b>	Present
Lactose Monohydrate	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	Not Listed
Nirmatrelvir	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	Not Listed
Opadry Pink	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	Not Listed
Croscarmellose sodium	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	Not Listed
<b>AICS</b>	Present
Sodium stearyl fumarate	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	223-781-1
+ Silicon dioxide, NF	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	carcinogen 10/1/1988 airborne particles of respirable size
<b>TSCA</b>	Present
<b>EINECS</b>	231-545-4
<b>AICS</b>	Present

## France

### Occupational Illnesses (R-463-3, France)

Chemical name	French RG number	Title
Microcrystalline cellulose 9004-34-6	RG 66	-
+ Silicon dioxide, NF 7631-86-9	RG 25	-

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

### Persistent Organic Pollutants

Not applicable

### Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

# SAFETY DATA SHEET

Product Name Nirmatrelvir Film-Coated Tablets  
Revision date 02-Feb-2022

Page 11 / 11  
Version 2.02

---

## **Legend:**

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

## **15.2. Chemical safety assessment**

**Chemical Safety Report** No information available

## **Section 16: OTHER INFORMATION**

### **Key or legend to abbreviations and acronyms used in the safety data sheet**

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

**Reason for revision** Updated Section 4 - First Aid Measures. Updated Section 11 - Toxicology Information.

**Revision date** 02-Feb-2022

**Prepared By** Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.